{"denoms":[{"counts":[{"groupId":"BG000","value":"254"}],"units":"Participants"}],"groups":[{"description":"Participants received bortezomib (Velcade) 1.3 milligram per square meter (mg/m\\^2) subcutaneously (SC) on Days 1, 4, 8, and 11; cyclophosphamide 300 mg/m\\^2 orally on Days 1, 8, and 15; and dexamethasone 20 milligram (mg) orally on Days 1, 2, 4, 5, 8, 9, 11, and 12 in three 21-day treatment cycles. Participants who completed induction phase entered into the consolidation treatment phase.","id":"BG000","title":"Bortezomib + Cyclophosphamide + Dexamethasone (VCD Induction)"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"7.76","value":"57.8"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"109"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"145"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"207"}]}],"title":"Australia"},{"categories":[{"measurements":[{"groupId":"BG000","value":"17"}]}],"title":"China"},{"categories":[{"measurements":[{"groupId":"BG000","value":"30"}]}],"title":"Republic of Korea"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Region of Enrollment","unitOfMeasure":"Participants"}],"populationDescription":"Baseline population was defined as all enrolled participants who received at least 1 non-zero dose of any study drug in the induction phase."}